ADMA Biologics (NASDAQ:ADMA) Cut to “Strong Sell” at Zacks Research

ADMA Biologics (NASDAQ:ADMA) was downgraded by stock analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a research report issued to clients and investors on Tuesday,Zacks.com reports.

ADMA has been the subject of a number of other reports. Canaccord Genuity Group decreased their price objective on ADMA Biologics from $21.00 to $18.00 and set a “buy” rating for the company in a research note on Thursday, May 7th. Mizuho cut their price target on shares of ADMA Biologics from $20.00 to $17.00 and set an “outperform” rating on the stock in a research note on Wednesday, July 15th. Raymond James Financial started coverage on shares of ADMA Biologics in a report on Wednesday, June 10th. They set an “outperform” rating and a $21.00 price objective on the stock. Wall Street Zen downgraded ADMA Biologics from a “buy” rating to a “hold” rating in a research note on Monday, May 4th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of ADMA Biologics in a research note on Thursday, June 18th. Three investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, ADMA Biologics has an average rating of “Hold” and an average price target of $18.67.

ADMA Biologics Stock Up 3.9%

NASDAQ ADMA opened at $9.26 on Tuesday. The company has a quick ratio of 3.93, a current ratio of 6.95 and a debt-to-equity ratio of 0.51. The firm has a market capitalization of $2.15 billion, a price-to-earnings ratio of 13.62 and a beta of 0.74. ADMA Biologics has a 52 week low of $7.21 and a 52 week high of $20.46. The company has a fifty day moving average of $8.55 and a two-hundred day moving average of $11.37.

ADMA Biologics (NASDAQ:ADMA) last posted its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $0.16 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.16. The company had revenue of $124.39 million during the quarter, compared to analysts’ expectations of $125.34 million. ADMA Biologics had a return on equity of 39.98% and a net margin of 32.43%.ADMA Biologics’s revenue was up 2.0% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.14 EPS. On average, analysts predict that ADMA Biologics will post 0.8 earnings per share for the current year.

Insider Activity

In other ADMA Biologics news, Director Jerrold B. Grossman purchased 12,500 shares of the firm’s stock in a transaction dated Monday, May 11th. The shares were purchased at an average cost of $8.01 per share, with a total value of $100,125.00. Following the completion of the purchase, the director owned 513,884 shares in the company, valued at approximately $4,116,210.84. This represents a 2.49% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this link. 3.90% of the stock is owned by insiders.

Hedge Funds Weigh In On ADMA Biologics

A number of institutional investors have recently bought and sold shares of the company. Royal Bank of Canada grew its stake in shares of ADMA Biologics by 112.7% in the first quarter. Royal Bank of Canada now owns 95,885 shares of the biotechnology company’s stock valued at $1,903,000 after buying an additional 50,801 shares in the last quarter. Ashton Thomas Private Wealth LLC purchased a new position in shares of ADMA Biologics in the 1st quarter valued at $217,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in ADMA Biologics by 59.6% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 816,590 shares of the biotechnology company’s stock worth $16,201,000 after buying an additional 305,064 shares during the period. Norges Bank acquired a new stake in ADMA Biologics during the 2nd quarter worth $549,000. Finally, EverSource Wealth Advisors LLC raised its stake in ADMA Biologics by 385.8% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,745 shares of the biotechnology company’s stock valued at $50,000 after acquiring an additional 2,180 shares during the last quarter. 75.68% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about ADMA Biologics

Here are the key news stories impacting ADMA Biologics this week:

• Positive Sentiment: ADMA reported second-quarter revenue of $124.4 million, up 2% year over year, while GAAP net income rose 11% to $37.8 million. Adjusted EBITDA increased 22% to $61.8 million, supporting the company’s profitability profile. ADMA Biologics Reports Second Quarter 2026 Financial Results and Provides Business Update
• Positive Sentiment: Quarterly EPS met the $0.16 analyst consensus, and ASCENIV revenue climbed 24% to $102.9 million. Management also said BIVIGAM demand and revenue stabilized sequentially, indicating improving utilization trends. ADMA Biologics Q2 Earnings Snapshot
• Positive Sentiment: The company reiterated 2026 revenue guidance of $530 million to $560 million, broadly consistent with the $534.9 million consensus estimate, and is targeting more than $200 million in share repurchases. Buybacks could provide demand for the stock and increase per-share value if executed. ADMA Reiterates 2026 Guidance and Targets Share Repurchases
• Neutral Sentiment: Management highlighted new real-world evidence on ASCENIV’s patient outcomes and healthcare-resource utilization, potentially supporting longer-term demand, although the evidence remains an upcoming catalyst rather than a reported financial result.
• Negative Sentiment: Multiple law firms are promoting a securities-fraud class action covering investors who purchased ADMA securities from August 9, 2024, through March 25, 2026. The complaints allege misleading statements involving revenue, financial condition, inventory distribution and business practices. Lead-plaintiff notices cite an August 10 deadline. The allegations have not been proven, but the litigation creates legal costs, reputational risk and potential financial exposure. ADMA Securities Fraud Lawsuit Notice

About ADMA Biologics

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.